ASCO 2022 | Sitravatinib and nivolumab in ccRCC following progression on antiangiogenic therapy
Pavlos Msaouel
• 3 Jun 2022
Pavlos Msaouel, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, reports on the findings of a Phase I/II trial of sitravatinib and nivolumab in patients with clear cell renal cell carcinoma (ccRCC) following progression on antiangiogenic therapy. The combination demonstrated no unexpected toxicities and achieved an objective response rate of 35.7% and a median progression-free survival of 11.7 months, with 80.1% of patients alive after a median follow-up of 18.7 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
